Profile 1: Personal or Family History of Medullary Thyroid Carcinoma or MEN2 This is an absolute contraindication listed in the FDA black box warning for every approved GLP-1 receptor agonist, including semaglutide and tirzepatide [3][4]
2017;25:20 Lu Y, Wu L, Lin M, Bao X, Zhong H, Ke P, et al
This is a prescriber-level decision, not a dose-level decision, but it influences whether retatrutide is appropriate for you at all
Understanding the comparison means understanding that these are complementary strategies, not two versions of the same drug
This means that the positive inotropic effect that we described in this report occurred at plasma concentrations that are found in patients
What those companies are selling is completely unknown